$CING News

Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy

HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target

CING: Building Its Cash Position

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate

Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $55

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Cingulate Files Prospectus Supplement Related To Issuance And Sale Of Common Stock Of Up To $100M From Time To Time

Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14

CING: Laying the Foundation for 1H:27 Launch

What's Going On With Cingulate Stock Today?

Cingulate shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Cingulate shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Cingulate Q4 EPS $(0.84) Misses $(0.61) Estimate

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cingulate Files For Mixed Shelf Offering Of Up To $200M

Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58